Drug intelligence / Profile preview

HuGuXiaoJiTang

Development stage: Unknown
Lead developer: Guangzhou University of Chinese Medicine
Administration: Oral

Overview

HuGuXiaoJiTang (HGXJT) is a Traditional Chinese Medicine (TCM) herbal decoction developed by Guangzhou University of Traditional Chinese Medicine for the treatment of non-small cell lung cancer (NSCLC) with bone metastases. The formula is designed to be administered in combination with standard-of-care immune checkpoint inhibitors (ICIs) and chemotherapy. It aims to provide bone protection and exert anti-tumor effects (mass-dispersing) by modulating the tumor and bone microenvironments. HGXJT is currently being evaluated in a Phase 2 clinical trial (NCT05378334) to determine its efficacy and safety in improving clinical outcomes for patients with advanced NSCLC and skeletal involvement.

Other names: Bone-Protecting and Mass-Dispersing DecoctionBone Protecting and Anti-accumulation FormulaHuGuXiaoJiTang

Beyond the preview

Go deeper on HuGuXiaoJiTang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HuGuXiaoJiTang.

Explore the full profile